Laboratory of Host Pathogen Interaction in Livestock, Division of Animal and Human Health Engineering, Department of Biosystems, KU Leuven, 3001 Leuven, Belgium; Department of Biomedical Sciences, College of Veterinary Medicine and Agriculture, Addis Ababa University, P.O. Box 34, Bishoftu, Ethiopia.
Animal Health Institute (AHI), P.O. Box 04, Sebeta, Ethiopia.
J Infect Public Health. 2024 May;17(5):741-747. doi: 10.1016/j.jiph.2024.03.003. Epub 2024 Mar 13.
Infectious diseases impose a significant burden on the global public health and economy, resulting in an estimated 15 million deaths out of 57 million annually worldwide. This study examines the current state of CRISPR-Cas12/Cas13 research, focusing on its applications in infectious disease detection and its evolutionary trajectory.
A bibliometric analysis and systematic review were conducted by retrieving CRISPR-Cas12/Cas13-related articles published between January 1, 2015 to December 31, 2022, from the Web of Science database. The research protocol was registered with International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202380062).
Our search identified 1987 articles, of which, 1856 were included in the bibliometric analysis and 445 were used in qualitative analysis. The study reveals a substantial increase in scientific production on CRISPR-Cas12/Cas13, with an annual growth rate of 104.5%. The United States leads in the number of published articles. The systematic review identified 580 different diagnostic assays targeting 170 pathogens, with SARS-CoV-2 dominating with 158 assays. Recombinase polymerase amplification (RPA)/reverse transcription-RPA (RT-RPA) emerged as the predominant amplification method, while lateral flow assay was the most common readout method. Approximately 72% of the diagnostic assays developed are suitable for point-of-care testing.
The rapid increase in research on CRISPR-Cas12/Cas13 between 2015 and 2022 suggests promising potential for advancements in infectious disease diagnosis. Given the numerous advantages of CRISPR-Cas technology for disease detection over other methods, and the dedicated efforts of scientists from around the world, it is reasonable to anticipate that CRISPR-Cas technology may emerge as a formidable alternative, offering the possibility of expedited point-of-care testing in the not-too-distant future.
传染病对全球公共卫生和经济造成了重大负担，导致全球每年约有 1500 万人死亡。本研究考察了 CRISPR-Cas12/Cas13 研究的现状，重点关注其在传染病检测中的应用及其进化轨迹。
通过从 Web of Science 数据库中检索 2015 年 1 月 1 日至 2022 年 12 月 31 日期间发表的与 CRISPR-Cas12/Cas13 相关的文章，进行文献计量分析和系统综述。该研究方案在国际注册系统评价和荟萃分析方案（INPLASY202380062）上进行了注册。
我们的搜索共确定了 1987 篇文章，其中 1856 篇纳入文献计量分析，445 篇用于定性分析。研究表明，CRISPR-Cas12/Cas13 的科学研究呈显著增长，年增长率为 104.5%。美国在发表文章数量上处于领先地位。系统综述确定了针对 170 种病原体的 580 种不同诊断检测方法，其中 SARS-CoV-2 占据主导地位，有 158 种检测方法。重组酶聚合扩增（RPA）/逆转录-RPA（RT-RPA）成为最主要的扩增方法，而侧向流动检测是最常见的读取方法。约 72%的开发诊断检测方法适合即时检测。
2015 年至 2022 年期间，CRISPR-Cas12/Cas13 的研究迅速增加，表明其在传染病诊断方面具有很大的发展潜力。鉴于 CRISPR-Cas 技术在疾病检测方面相对于其他方法具有众多优势，以及世界各地科学家的努力，有理由预计 CRISPR-Cas 技术可能成为一种强有力的替代方法，在不久的将来可能实现即时检测。
